Brandon Scalea

Articles

Herbst Highlights Next Steps With Immunotherapy in Lung Cancer

November 13th 2018

Roy S. Herbst, MD, PhD, discusses where future research is headed for immunotherapy in lung cancer.

Camidge Breaks Down Oncogene-Driven NSCLC

November 11th 2018

D. Ross Camidge, MD, PhD, discusses the crowded landscape of oncogene-driven non–small cell lung cancer.

Redefining the Role of Cytoreductive Nephrectomy in RCC

November 10th 2018

Peter E. Clark, MD, discusses the role of surgery in the rapidly evolving treatment paradigm for patients with renal cell carcinoma.

Acquired Resistance Remains Key Challenge in Oncogene-Driven NSCLC

November 9th 2018

Balazs Halmos, MD, MS, discusses overcoming acquired resistance and other next steps needed to advance the oncogene-driven non–small cell lung cancer paradigm.

Frontline Paradigm Continues to Evolve in RCC

November 2nd 2018

Claud M. Grigg, Jr, MD, discusses the evolving treatment options in the frontline setting for patients with renal cell carcinoma.

Lead Investigator Highlights Pembrolizumab Potential in BCG-Resistant Bladder Cancer

November 2nd 2018

Ronald de Wit, MD, PhD, discusses the clinical implications of pembrolizumab in the non–muscle invasive bladder cancer patient population.

Immunotherapy Combinations Taking Shape in RCC

November 1st 2018

Asim Amin, MD, discusses the current role of checkpoint inhibitors in advanced renal cell carcinoma and where the future is heading in this space.

Burgess Shares Insight on Evolving Prostate Cancer Paradigm

October 31st 2018

Earle Burgess, MD, discusses the shifting paradigm of metastatic castration-sensitive prostate cancer.

Biosimilars Among Several Measures Needed to Lower Oncology Costs

October 31st 2018

Kashyap Patel, MD, discusses biosimilars and other potential cost-controlling measures in cancer care.

Thoracic Oncologist Highlights EGFR TKI Advances in NSCLC

October 30th 2018

Missak Haigentz, MD, discusses the impact of EGFR TKIs on the treatment of patients with non–small cell lung cancer.

Emerging Agents, TKI Discontinuation Focal Points of CML Research

October 29th 2018

Neil P. Shah, MD, PhD, discusses emerging agents and the tyrosine kinase inhibitor discontinuation approach in the landscape of chronic myeloid leukemia.

Expert Discusses MINDACT, TAILORx Studies in Breast Cancer

October 29th 2018

Michelle E. Melisko, MD, discusses the clinical implications of the TAILORx and MINDACT studies.

Markman Reflects on Career, Progress in Gynecologic Cancers

October 29th 2018

Maurie Markman, MD, reflects on practice-changing advances during his career and discussed the future of gynecologic cancer treatment.

UCSF Expert Highlights Progress in Lymphoma Landscape

October 29th 2018

Lawrence D. Kaplan, MD, discusses recent updates and next steps in the expanding paradigm of Hodgkin lymphoma, mantle cell lymphoma, and follicular lymphoma.

Expert Discusses Durvalumab and Future of Immunotherapy in NSCLC

October 28th 2018

Neil Morganstein, MD, discusses the intriguing PACIFIC results and the future role of immunotherapy in non–small cell lung cancer.

CLL Paradigm Rapidly Evolving With Novel Agents

October 25th 2018

Brian T. Hill, MD, PhD, discusses recent advances and regulatory decisions in the treatment of patients with chronic lymphocytic leukemia.

Borghaei Shares Insight on Immunotherapy in NSCLC

October 25th 2018

Hossein Borghaei, DO, MS, discusses immunotherapy selection for the treatment of patients with non–small cell lung cancer.

Sequencing Strategies, Combinations Mark Next Steps in HCC

October 23rd 2018

Josep M. Llovet, MD, PhD, discusses the rapidly evolving treatment landscape for hepatocellular carcinoma and the work that lies ahead.

Immunotherapy Research Key to Moving SCLC Field Forward

October 23rd 2018

Ramsey N. Asmar, MD, discusses recent advances and next steps in small cell lung cancer.

Recent Approvals Move Needle for Nonmetastatic CRPC

October 23rd 2018

Deborah A. Bradley, MD, discusses how recent clinical trials have impacted patients with nonmetastatic castration-resistant prostate cancer and what the future holds for them.